Sickle cell anemia requires ongoing ... Hydroxyurea causes the body to produce fetal hemoglobin, a type of hemoglobin that is normally produced only before and shortly after birth.

Beam Therapeutics enrolls 35 patients in BEACON trial for BEAM-101 in sickle cell disease, with promising early safety and ...

A person with one abnormal hemoglobin gene and one typical hemoglobin ... The most severe form of SCD is sickle cell anemia. If parents are considering having a child and are concerned about ...

The hemoglobin elevating agent is being developed for the treatment of anemia associated with multiple diseases.

Beam Therapeutics has presented the first clinical data on its base editing technology. | Beam Therapeutics has presented the ...

Sickle Cell Disease Market Size Was Valued at USD 2.40 Billion in 2023, and is Projected to Reach USD 12.38 Billion by 2032, ...

The death, which investigators linked to a preparatory chemo treatment rather than Beam's medicine, highlights the risks of using decades-old transplant drugs alongside cutting-edge CRISPR medicines.

Newborn screening, comprehensive care, and disease-modifying therapies are changing the outlook for patients with sickle cell ...

A patient with sickle cell disease died while participating in a clinical trial of a CRISPR-based treatment from Beam Therapeutics, threatening to overshadow early signals of effective gene editing.

According to Uganda's Ministry of Health, around 250,000 people in the country live with sickle cell disease, including an estimated 20,000 to 25,000 babies ...

After 44 days at the Children’s National Hospital in Washington, D.C., Kendric Cromer has left the hospital free of sickle cell disease. Cromer is the first patient to undergo a recently approved gene ...

The Pt Deendayal Upadhyay Memorial Health Sciences and Ayush University collaborates with CSIR-CCMB to enhance sickle cell anemia diagnosis and genetic research, improving public health outcomes in ...